BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and financial results for the three and nine months ended September 30, 2020.

- Amgen (NASDAQ:AMGN) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference at 4:15 p.m. ET on Monday , Nov. 9, 2020, in Scottsdale, Ariz. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen and Peter H. Griffith , executive vice president and chief financial officer, wil

Stealth to receive up to $35 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (“Lilly”, NYSE: LLY) jointly announce that results of seven clinical studies of TYVYT®

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2020 and provided an update on its product pipeline and corporate activities.

Kadmon Holdings, Inc. announced that 12-month data from ROCKstar, the ongoing pivotal trial of belumosudil for the treatment of chronic graft-versus-host disease, have been selected for oral presentation at the 62nd American Society of Hematology Annual Meeting, taking place virtually December 5 - 8, 2020.

BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on November 1, 2020, the compensation committee of BridgeBio’s board of directors granted three new employees restricted stock units for an aggregate of 9,566 shares of the Company’s common stock.

Interim data from Phase 2 study showed that once-weekly formulation of setmelanotide achieved safety and efficacy results comparable to daily-dosing formulation

Centene Corporation (NYSE: CNC) announced today it will participate at two virtual conferences this month. On Tuesday, November 10 , at 8:45 a.m. Eastern Standard Time (EST), Centene will participate in a virtual format at the Credit Suisse 29 th Annual Healthcare Conference. A simultaneous live audio webcast is available at: ht

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference.